Nitric oxide and its antithrombotic action in the cardiovascular system

Current Drug Targets - Cardiovascular and Haematological Disorders

Volumn 5, Issue 1, 2005, Pages 65-74

  Gustavo, Reichenbach ^a   Stefania, Momi ^a   Paolo, Gresele ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Atherosclerosis; Cardiovascular system; Myoglobin; Nitric oxide; Nitric oxide donors; Nitric oxide scavengers; Nitroaspirin; Oxygen radicals; Platelet aggregation; Thrombosis; Vasodilation

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ACETYLSALICYLIC ACID DERIVATIVE; ANTIOXIDANT; ARGININE; ASCORBIC ACID; CYCLIC GMP; CYTOCHROME; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTATHIONE; GLYCERYL TRINITRATE; HEMOGLOBIN; IMINE; INDUCIBLE NITRIC OXIDE SYNTHASE; MYOGLOBIN; NITRATE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE INHIBITOR; NITRITE; NITROPRUSSIDE SODIUM; NITROSAMINE; NITROSO DERIVATIVE; OXYGEN RADICAL; PORPHYRIN DERIVATIVE; S NITROSOGLUTATHIONE; S NITROSOTHIOL; SCAVENGER; SILDENAFIL; THIOL DERIVATIVE; UNINDEXED DRUG;

ANGINA PECTORIS; ARTERY DISEASE; ATHEROSCLEROSIS; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYSTEM; CELL FUNCTION; CLINICAL TRIAL; DIABETES MELLITUS; DNA DAMAGE; DRUG MECHANISM; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LUNG DISEASE; LUNG EMBOLISM; MODULATION; MOLECULAR MECHANICS; NONHUMAN; PATHOLOGY; PREGNANCY; REPERFUSION INJURY; RESTENOSIS; REVIEW; SCAVENGING SYSTEM; SEPTIC SHOCK; SPECTROSCOPY; STOMACH DISEASE; THROMBOCYTE; THROMBOSIS; UNSTABLE ANGINA PECTORIS; VASODILATATION;

ANIMALS; ANTICONVULSANTS; DRUG DESIGN; EPILEPSY; HUMANS; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN ANTAGONISTS;

EID: 13844255553     PISSN: 15680061     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568006053005047     Document Type: Review

References (135)

1. Suslick,K.S.; Reinert,T.J.The synthetic analogs of O2-binding heme proteins. J. Chem. Ed., 1985, 974.
2. Spiro, T.G; Zgierski; M.Z.;Kozlowski,P.M.Stereoelectronic factors for NO from vibrational spectroscopy. Coord.Chem. Rev. 2001, 219, 923.
3. Richter-Addo, G.B.; Wheeler, R.A.; Hixson, C.A.; Chen, L.; Khan, M.A.; Ellison, M.K.; Schulz, C.E.; Scheidt, W.R. Unexpected nitrosyl-group bending in six-coordinate (M(NO))(6) sigma-bonded aryl(iron) and-(ruthenium) porphirins. J. Amer. Chem. Soc. 2001 123, 6314.
4. Koshland, D.E. Science The molecule of the year. 1992, 258, 1861.
5. Richter-Addo, G.B.; Legzdins, P.; Burstin, J. Nitric oxide chemistry. Chem. Rev. 2002, 102, 857.
6. Nitric Oxide. Second international conference of the nitric oxide society. 2002, 6, 353.
7. Loscalzo, J.; Vita, J.A. Nitric oxide and the cardiovascular system. Totowa, Humana Press Inc., 2000.
8. Murad, F. Discovery of some of the biological effects of nitric oxide and its role in cell signaling. Biosci. Rep. 1999 19, 133.
9. Furchgott, R.F. Endothelium-derived relaxing factor: discovery, early studies, and identification as nitric oxide. Biosci. Rep. 1999, 19, 235.
10. Ignarro, L.J. Nitric oxide: a unique endogenous signaling molecule in vascular biology (Nobel lecture). Angew. Chem. Int. Ed. Eng. 1999, 38, 1882.
11. Stamler, J.S.; Simon, D.I.; Osborne, J.A.; Mullins, M.E.; Jaraki, O.; Michel, T.; Singel, D.J.; Loscalzo, J. S-nitrosylation of proteins with NO: synthesis and characterisation of biological active compounds. Proc. Natl. Acad.Sci. USA 1992, 89, 444.
12. Pawloski, J.R.; Hess, D.T.; Stamler, J.S. Export by red blood cells of NO bioactivity. Nature, 2001, 409, 622.
13. Gross,S.S. Targeted delivery of NO. Nature, 2001, 409, 577.
14. Witting,P.K.;Douglas,D.J.; Mauk,A.G. Reaction of human myoglobin and NO. J. Biol. Chem., 2001, 276, 3991.
15. Reichenbach, G.; Sabatini, S.; Palombari, R.; Palmerini, C.A. Reaction mechanism between NO and glutathione mediated by Fe(III) myoglobin. Nitric Oxide, 2001, 5, 395.
16. Boccini, F. Cinetiche di riduzione del citocrono c da parte della 1-cisteina. Universitary Thesis Perugia 2002.
17. Demoncheaux, E.A.G.; Higenbottam, T.W.; Foster, P.J.; Borland, C.D.R.; Smith, A.P.L.; Mariott, H.M.; Bee, D.; Akamine, S.; Davies, M.B. Circulating nitrite anion are a directly acting vasodilator and are donors for NO. Clin. Sci. 2002, 102, 77.
18. Tsikas,D.; Frölich, J.C. Is circulating nitrite a directly acting vasodilator? Clin. Sci. 2002, 103, 107.
19. Demoncheaux, E.A.G.; Higenbottam, P.G.; Foster, P.J.; Borland, C.D.R.; Smith, A.P.L.; Mariott, H.M.; Bee, D.; Akamine, S.; Davies, M.B. Is circulating nitrite a directly acting vasodilator? Author's reply. Clin. Sci. 2002, 103, 108.
20. Wang, P.G.; Xiang, M.; Tang, X.; Wu, X.; Wen, Z.; Cai, T.; Janczuk, A.J. NO donors: chemical activities and biological applications. Chem.Rev. 2002, 102, 7.
21. Ding, X.D.; Weichsel, A.; Andersen, J.F.; Shokhireva, T.K.; Balfour, C.; Pierik, A.J.; Averill, B.A.; Montfort, W.R.; Walker, F.A. NO binding to the ferri- and ferroheme states of nitrophorin 1, a reversible NO-binding heme protein from the saliva of the blood-sucking insect, Rhodnius prolixus. J. Amer. Chem. Soc. 1999, 121, 128.
22. Schünemann, V.; Benda, R.; Trautwein, A.X.; Walker, F.A. Mossbauer Spectroscopic studies of the six-coordinate heme-NO complex of iron (III) octaethylporfirin N-metylimidazole, the first model of the nitrophorin-NO complexes. Israel J. Chem. 2000, 40, 9.
23. Seidler, M.; Uckert, S.; Waldkirch, E.; Stief, C.G.; Oelke, M.; Tsicas, D.; Sohn, M.; Jonas, U. In vitro effects of a novel class of NO donating compounds on isolated human erectile tissue. European Urology 2002, 42, 523.
24. Chung, P.; Cook, T.; Liu, K.; Vodovotz, Y.; Zamora, R.; Finkelstein, S.; Billiar, T.; Blumberg, T. Overexpression of the human inducible NO synthase gene enhances radiation-induced apoptosis in colorectal cancer cells via a caspase-dependent mechanism. Nitric Oxide 2003, 8, 119.
25. Esumi, H.; Ogura, T.; Kurashima, Y.; Adaki, H.; Hokari, A.; Weisz, A. Implication of NO synthase in carcinogenesis: analysis of the human inducible NOS gene. Pharmacogenetics 1999, 5, 166.
26. Iwase, Y.; Takemura, Y.; Juichi, Y.; Yano, M.; Ito, C.; Furukava, H.; Mukainaka, T.; Kuchida, M.; Tokuda, H.; Nishino, H. Cancer chemoprotective activity of 3,5,6,7,8,3′,4′-heptamethoxyflavone from the peel of citrus plant. Cancer Letter 2001, 163, 7.
27. Schon, T.; Elias, D.; Moges, F.; Melese, E.; Tessema, T., Stendahl, O.; Britton, S.; Sundqvist, T. Arginine as an adjuvant to chemotherapy improves clinical outcome in active tubercolosis. European Respiratory J. 2003, 21, 483.
28. Akaike, T. Role of free radicals in viral pathogenesis and mutation. Rev. Med. Virol. 2001, 11, 87.
29. Akaike, T.; Okamoto, S.; Sawa, T.; Yoshitake, J.; Tamura, F.; Ichimori, K.; Miyazaki, K.; Sasamoto, K., Maeda, H. 8-nitroguanosine formation in viral pneumonia and its implication for pathogenesis. Proc. Natl. Acad. Sci. USA 2003, 100.
30. Dzgoeva, F.U.; Kutyrina, I.M.; Burgova, E.N.; Salbiev, K.D.; Vanin, A.F. Decrease in kidney NO formation detected by electron paramagnetic resonance in acute renal failure due to contrast media. Nephron 1999, 81, 441.
31. Longo, M.; Jain, V.; Vedernikov, Y.P.; Saade, G.R.; Goodrum, L.; Fachinetti, F.; Garfield, R.E. Effect of NO and CO on uterine contractility during human and rat pregnacy. Am. J. Obstet. Gynecol. 1999, 181, 981.
32. Fulep, E.E.; Vedernikov, Y.P.; Saade, G.R.; Garfield, R.E. Responses of isolated perfused uterine vascular beds of nonpregnant and pregnant rats to endogenous and exogenous NO. General Pharmacology, 2002, 35, 297.
33. Richardson, G.; Benjamin, N. Potential therapeutic uses of S-nitrosothiols. Clinical Science 2002, 102, 99.
34. Wang, P.G.; Xiang, M.; Tang, X.; Wu, X.; Wen, Z.; Cai, T.; Janczuk, A.J. NO donors : Chemical activities and biological applications. Chem. Rev. 2002, 102, 1091.
35. Hrabie, J.A.; Keefer, L.K. Chemistry of NO-releasing diazeniumdiolates ("Nitrosohydroxylamine") functional group and its oxygen-substituted derivatives. Chem. Rev. 2002, 102, 1135.
36. Ruane, P.H.; Bushan, K.M.; Pavlos, C.M.; D'Sa, R.A.; Toscano, J.P. Controlled photochemical release of NO from O2-benzyl-substituted diazeniumdiolates. J. Amer. Chem. Soc. 2002, 124, 9806.
37. Saavedra, J.E.; Shami, P.J.; Wang, L.Y.; Davies, K.M.; Booth, M.N.; Citro, M.L.; Keefer, L.K. Esterase-sensitive NO donors of the diazeniumdiolates family: in vitro antileukemic activity. J. Med. Chem. 2000, 43, 261.
38. Lopez, B.L.; Kreshak, A.A.; Allyson, A.; Morris, C.R.; Davis-Moon, L.; Ballas, S.K.; Ma, X-L. L-Arginine levels are diminished in adult acute vaso-occlusive sickle cell crisis in the emergency departement. British J. Hematology 2003, 120, 532.
39. Griffiths, T.; Yamini, B.; Hall, C.; Garthwaite, J. NO inactivation in brain by a novel O2-dependent mechanism resulting in the formation of nitrate ion. Biochem. J. 2002, 363 893.
40. Fishlock, D.; Perdicakis, B.; Montgomery, H.J.; Heather, J.; Guillemette, J.G.; Jervis, E.; Lajoie, G.H. Sinthesis and evaluation of trans 3,4-cyclopropyl L-arginine analogues as isoform selective inhibitors of NOsynthase. Bioorganic Medicinal Chem. 2003, 11, 869.
41. Hallinan, E.A.; Tsymbalov, S.; Dorn, C.R.; Pitzele, B.S.; Barnett, S.; Hansen, D.W. Jr.; Moore, W.M.; Jerome, G.M.; Connor, J.R., Branson, L.F.; Widomski, D.L.; Zhang, Y.; Currie, M.G.; Manning, P.T. Synthesis and biological characterization of L-N6- (1-imminoethyl) lysine 5-tetrazole-amide, a prodrug of a selective iNOS inhibitor. J. Med. Chem. 2002, 45, 1686.
42. Boveris, A.; Arnaiz, S.L.; Bustamante, J.; Alvarez, S.; Valdez, L.; Boveris, A.D.; Navarro, A. Pharmacological regulation of mitochondrial NO synthase. Methods in Enzymology 2002, 359 328.
43. Herold, S.; Röck, G. Reactions of deoxy-,oxy and methemoglobin with NO. J. Biol. Chem. 2003, 278, 6623.
44. Flögel, U.; Merx, M.W.; Gödecke, A.; Decking, U.K.M.; Schrader, J. Myoglobin: a scavenger of bioactive NO. Proc. Natl. Acad. Sci. USA 2001, 98, 735.
45. Zheng, D.; Birke, R.L. The reaction of NO with glutathionylcobalamin. J. Amer. Chem. Soc. 2002, 124, 9066.
46. Herold, S.; Exner,M.;Boccini, F. The mechanism of the peroxynitrite-mediated oxidation of myoglobin in the absence and presence of carbon dioxide. Chem. Res. Toxicol. 2003,
47. Garry, D.J.; Ordway, G.A.; Lorenz, J.N.; Radford, N.B.; Chin, E.R.; Grange, R.W.; Bassel-Duby, R.; Williams, R.S. Mice without myoglobin. Nature, 1998, 395, 905.
48. Green, L.C.; Wagner, D.A.; Glogowski, J.; Skipper, P.L.; Wishnok, J.S.; Tannenbaum, R.S. Analysis of nitrate, nitrite and (N15) nitrite in biological fluids. Anal. Biochem. 1982, 126, 131.
49. Wink, D.A.; Kim, S.; Coffin, D.; Cook, J.S.;Vodovotz; Chistodoulou, D.; Jourd'heuil D.; Grisham, M.B. Detection of S-nitrosothiols by fluorometric and colorimetric methods.Methods Enzymol. 1999, 301, 227.
50. Kostka, P.; Park, J.K. Fluorometric detection of S-nitrosothiols. Methods Enzym. 1999, 301, 27.
51. Clancy, R.; Cederbaum, A.I.; Stoyanovsky, D.A. Preparation and properties of S-nitroso-L-cysteine ethyl ester, an intracellular nitrosating agent. J. Med. Chem. 2001, 44, 2035.
52. Cammack, R.; Shergill, J.K.; Inalsingh, V.A.; Hughes, M.N. Application of electron paramagnetic resonance spectroscopy to study interactions of iron proteins in cells with NO. Spectrochim. Acta Part A. 1998, 54, 2393.
53. Gladwin, M.T.; Ognibene, F.P.; Pannell, L.K.; Nichols, J.S.; Pease-Fye, M.E. Shelhamer, J.K.; Schechter, A.N. Relative role of heme nitrosylation and beta-cysteine 93 nitrosation in the trasport and metabolism of NO by hemoglobin in the human circulation. Proc. Natl. Acad. Sci. USA 2000, 97, 9943.
54. Palmerini, C.A.; Arienti, G.; Mazzolla, R.; Palombari, R. A new assay for the determination of low-molecular-weight nitosothiols (nitrosoglutathione), NO and nitrites by using a specific and sensitive solid-state amperometric gas sensor. Nitric Oxide 1998, 2,375.
55. Furchgott, R.F.; Zawadzki, J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle cells by acetylcholine. Nature 1988, 245, 524.
56. Stamler, J.S.; Vaughan, D.E.; Loscalzo, J. Synergistic disaggregation of platelets by tissue-type plasminogen activator, prostaglandin E1 and nitroglycerin. Circ. Res. 1989, 65 796.
57. Loscalzo, J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ. Res. 2001, 88, 756.
58. Chen, L.Y.; Metha, J.L. Variable effects of L-arginine analogs on 1-arginine nitric oxide pathway in human neutrophils and platelets may relate to different nitric oxide synthase isoforms. J. Pharmacol. Exp. Ther. 1996, 276, 253.
59. Ignarro, L.J.; Buga, G.M.; Wei, L.H.; Bauer, P.M.; Wu, G.; Del Soldato, P. Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc. Natl. Acad. Sci. USA 2001, 98, 4202.
60. Napoli, C.; Cirino, G.; Del Soldato, P.; Sorrentino, R.; Sica, V.: Condorelli, M.; Pinto, A.; Ignarro, L.J. Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice. Proc. Natl. Acad. Sci. USA 2001, 98, 2860.
61. Napoli, C.: Aldini, G.; Wallace, J.L.; de Nigris, F.; Maffei, R.; Abete, P.; Bonaduce, D.; Condorelli, G.; Rengo, F.; Sica, V.; D'Armiento, C.M.; de Rosa, G.; Condorelli, M.; Lerman, L.O.; Ignarro, L.J. Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis. Proc. Natl. Acad. Sci. USA 2002, 99, 1689.
62. Yu, J.; Rudic, R.D.; Sessa, W.C. Nitric oxide-releasing aspirin decreases vascular injury by reducing inflammation and promoting apoptosis. Lab. Invest. 2002, 82, 825.
63. Cirino, G.; Napoli, C.; Sessa, W.C. Endothelial nitric oxide synthase: the Cinderella of inflammation? Trends. Pharmacol. Sci. 2003, 24, 91.
64. Sessa, W.C. The nitric oxide synthase family of proteins. J. Vasc. Res. 1994, 21, 131.
65. Schini-Kerth, V.B.; Vanhoutte, P.M. Nitric oxide syntahses in vascular cells. Exp. Physiol. 1995, 80, 885.
66. Kanai, A.J.; Strauss, H.C.; Truskey, G.A.; Crews, A.L.; Grunfeld, S.; Malinski, T. Shear stress induces ATP-independent transient 0nitric oxide release from vascular endothelial cells, measured directly with a porphyrinic microsensos. Circ. Res., 1995, 77, 284.
67. Cohen, R.A.; Vanhoutte, P.M. Endothelium-dependent hyperpolarization-Beyond nitric oxide and cyclic GMP. Circulation. 1995, 92, 3337.
68. Calderone, A. The therapeutic effect of natriuretic peptides in heart failure; differential regulation of endothelial and inducible nitric oxide synthases. Heart. Fail. Rev. 2003, 8, 55.
69. Gugliemini, G.; Monni, M.; Nenci, G.G.; Gresele, P. High shear stress induces nitric oxide synthesis in human platelets. Thromb. Haemost. 2001, Suppl. P1199.
70. Chen, L.Y.; Mehta, J.L. Further evidence of the presence of constitutive and inducible nitric oxide synthase isoforms in human platelets. J. Cardiovasc. Pharmacol. 1996, 27, 154.
71. MacMicking, J.; Xie, Q.W.; Nathan, C. Nitric oxide and macrophage function. Annu. Rev. Immunol. 1997, 15, 323.
72. Rao, K.M.K.; Padmanabhan, J.; Kilby, D.L.; Cohen, H.J.; Currie, M.S.; Weinberg, J.B. Flow cytometry analysis of nitric oxide production in human neutrophils using dichlorofluorescein diacetate in the presence of a calmodulin inhibitor. J. Leukocyte. Biol. 1992 51, 496.
73. Kojda, G.; Kottenberg, K. Regulation of basal myocardial function by NO. Cardiovasc. Res. 1999, 41, 514.
74. Yan, Z.; Hansson, G.K. Overexpression of inducible nitric oxide synthase by neointimal smooth muscle cells. Circ. Res. 1998, 82, 21.
75. Connelly, I.; Jacobs, A.T.; Palacios-Callender, M.; Moncada, S; Hobbs, A.J. Macrophage endothelial nitric oxide synthase autoregulates cellular activation and pro-inflammatory protein expression. J. Biol. Chem. 2003, 278, 26480.
76. Massberg, S.; Sausbier, M.; Klatt, P.; Bauer, M.; Pfeifer, A.; Siess, W., Fassler, R.; Ruth, P.; Krombach, F.; Hofmann, F. Increased adhesion and aggregation of platelet lacking cyclic guanosine 3′-5′ monophosphate kinase I. J. Exp. Med. 1999, 189, 1255.
77. Moro, M.A.; Russel, R.J.; Cellek, S.; Lizasoain, I.; Su, Y.; Darley Usmar, V.M.; Radomski, M.W., Moncada, S. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc. Natl. Acad. Sci. USA 1996, 93, 1480.
78. Willoughby, S. and Loscalzo, J. Vascular control of platelet function. In Platelets in thrombotic and non thrombotic disorders; Gresele P, Page CP, Fuster V, Vermylen J, Eds.; Cambridge University Press, Cambridge; 2002, pp. 432-455.
79. Malinski, T.; Radomski, M.W.; Taha, Z.; Moncada, S. Direct electrochemical measurement of nitric oxide released from human platelets. Biochem. Biophys. Res. Commun. 1993, 194, 960.
80. Freedman, J.E.; Loscalzo, J.M,; Barnard, M.R.; Alpert, C.; Keaney, J.F. Jr.; Michelson, A.D. Nitric oxide released from activated platelets inhibits platelet recruitment. J. Clin. Invest. 1997 100, 350.
81. Mezzasoma, A.M.; Leone, M.; Guglielmini, G.; Momi, S.; Del Soldato, P.; Gresele, P. Effects of nitroaspirin on platelet activation: potentiation by nitric oxide of the inhibitory effects of cyclooxygenase inhibition. Haematologica. 2000, 85 (Suppl 5), 84.
82. Radomski, M.W.; Palmer, R.M.J.; Moncada, S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc. Natl Acad. Sci. USA 1990, 87, 5193.
83. Michelson, A.D.; Bonoit, S.E.; Furman, M.I.; Breckwoldt, W.L.; Roher, M.J.; Barnard, M.R.; Loscalzo, J. Effects of nitric oxide/endothelium-derived relaxing factor on platelet surface glycoproteirs. Am. J. Physiol. 1996, 270, H1640.
84. Pigazzi, A.; Heydrick, S.; Folli, F.; Benoit, S.; Michelson, A.D.; Loscalzo, J. Nitric oxide inhibits thrombin receptor-activating peptide-induced phosphoinositide 3-kinase activity in human platelets. J. Biol. Chem. 1999, 273, 14368.
85. Fujimoto, Y.; Tagano, S.; Ogawa, K.; Sakuma, S.; Fujita, T. Comparison effects of nitric oxide and peroxinitrite on the 12-lipoxygenase and cyclooxygenase metabolism of arachidonic acid in rabbit platelets. Prostaglandins. Leukot. Essent. Fatty Acid 1998, 59, 95.
86. Corazzi, T.; Leone, M.; Roberti, R.; Del Soldato, P.; Gresele, P. Effect of nitric oxide-donating agents on human monocyte of cycloxygenase-2. Biochem. Biophys. Res. Commun. 2003, 311 897.
87. Freedman, J.E.; Ting, B.; Hankin, B.; Loscalzo, J.; Keaney, J.F.Jr.; Viat, J.A. Impaired platelet production of nitric oxide in patients with unstable angina. Circulation 1998, 98, 1481.
88. Freedman, J.E.; Loscalzo, J.; Benoit, S.E.; Valeri, C.R.; Barnard, M.R.; Michelson, A.D. Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. J. Clin. Invest. 1996, 97, 979.
89. Bodzenta-Lukaszyk, A.; Gabryelewicz, A.; Lukaszyk, A.; Bileawiec, M.; Konturek, J.W.; Domschke, W. Nitric oxide synthase inhibition and platelet function. Thromb. Res. 1994, 75 667.
90. Folts, J.D.; Gallagher, K.; Rowe, G.G. Blood flow reductions in stenosed canine coronary arteries: vasospasm or platelet aggregation. Circulation 1982, 65, 248.
91. Langford, E.J.; Brown, A.S.; Wainwright, R.J.; de Belder, A.J.; Thomas, P.K.; Smith, R.E.; Radomski, M.W.; Martin, J.F.; Moncada, S. Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty. Lancet. 1994, 344, 1485.
92. May, G.R.; Crook, P.; Moore, P.K.; Page, C.P. The role of nitric oxide as an endogenous regulator of platelet and neutrophil activation within the pulmonary circulation of the rabbit. Br. J. Pharmacol. 1991, 102, 759.
93. Lidbury, P.S.; Korbut, R.; Vane, J.R. Sodium nitroprusside modulates the fibrinolytic system in the rabbit. Br. J. Pharmacol. 1990, 101, 527.
94. Kawabata, A. Evidence that endogenous nitric oxide modulates plasma fibrinogen levels in the rat. Br. J. Pharmacol. 1996, 117, 236.
95. Emerson, M.; Momi, S.; Paul, W.; Alberti, P.F.; Page, C.P.; Gresele, P. Endogenous nitric oxide acts as a natural antithrombotic agent in vivo by inhibiting platelet aggregation in the pulmonary vasculature. Thromb. Haemost. 1999, 81, 961.
96. Freedman, J.E.; Sauter, R.; Battinelli, E.M.; Ault, K.; Knowles, C.; Huang, P.L.; Loscalzo, J. Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene. Circ. Res. 1999, 84, 1416.
97. Ikeda, H.; Takajo, Y.; Murohara, T.; Ichiki, K.; Adachi, H.; Haramaki, N.; Katoh, A.; Imaizumi, T. Platelet-derived nitric oxide and coronary risk factors. Hypertension 2000, 35, 904.
98. Morrow, J.D.; Frei, B.; Longmire, A.W.; Gaziano, J.M.; Lynch, S.M.; Shyr, Y.; Strass, W.E.; Oates, J.A.; Roberts, L.J. 2nd. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N. Engl. J. Med. 1995 332, 1198.
99. Stamler, J.S.; Singel, D.J.; Loscalzo, J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992, 258, 1898.
100. Takajo, Y.; Ikeda, H.; Haramaki, N.; Murohara, T.; Imaizumi, T. Augmented oxidative stress of platelets in chronic smokers. J. Am. Coll. Cardiol. 2001, 38, 1320.
101. Chirkov, Y.Y.; Holmes, A.S.; Willoughby, S.R.; Stewart, S.; Wuttke, RD.; Sage, P.R.; Horowitz, J.D. Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets. J. Am. Coll. Cardiol. 2001, 37, 1851.
102. Falk, E.; Zhou, J.; Moller, J. Homocysteine and atherothrombosis. Lipids 2001, 36, S3.
103. Mutus, B.; Rabili, R.A.; Staffolani, R.; Ricciotti, R.; Fumelli, P.; Moretti, N.; Martarelli, D.; Mazzanti, L. Homocysteine-induced inhibition of nitric oxide production in platelets: a study on healthy and diabetics subjects. Diabetologia. 2001 44, 979.
104. Gresele, P.; Lucarelli, G.; Mezzasoma, A.M.; Falcinelli, E.; Guglielmini, G. Platelet derived nitric oxide (NO) is suppressed in hyperhomocysteinemia: a possible prothrombotic effect. Thromb. Haemost 2003, 19th International Congress on Thrombosis and Haemostasis, Birmingham.
105. Furchgott, R,F. The 1996 Albert Lasker medical Research Awards. The discovery of endothelium-derived erlaxing factor and its importance in the identification of nitric oxide. JAMA 1996, 276, 1186.
106. Heitzer, T.; Schlinzing, T.; Krohn, K.; Meinertz, T.; Munzel, T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001, 104, 2673.
107. Li, J.; Zhao, S.P.; Li, X.P.; Zhuo, Q.C.; Gao, M.; Lu, S.K. Non-invasive detection of endothelial dysfunction in patients with essential hypertension. Int. J. Cardiol. 1997, 61, 165.
108. Creager, M.A.; Roddy, M.A. Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 1994, 24, 499.
109. Nelin, K.D.; Hoffman, G.M. The use of inhaled nitric oxide in a wide variety of clinical problems. Pediatr. Clin. North. Am. 1998, 45, 531.
110. Ignarro, L.J.; Cirino, G.; Casini, A.; Napoli, C. Nitric oxide as a signaling molecule in the vascular system: an overview. J. Cardiovasc. Pharmacol. 1999, 34, 879.
111. Keefer, L.K.; Nims, R.W.; Davies, K.M.; Wink, D.A. "ONOates" (1-subsituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. Methods. Enzymol. 1996, 268, 281.
112. Schonafinger, K. Heterocyclic NO prodrugs. Farmaco. 1999, 54, 316.
113. Hogg, N. Biological chemistry and clinical potential of S-nitrothiols. Free. Radic. Biol. Med. 2000, 28, 1478.
114. Gruetter, C.A.; Barry, B.K.; McNamara, D.B.; Gruetter, D.Y.; Kadowitz, P.J.; Ignarro, L. Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. J. Cyclic. Nucleotide. Res. 1979, 5, 211.
115. McGuire, J.J.; Anderson, D.J.; McDonald, B.J.; Naraynasami, R.; Bennett, B.M. Inhibition of NADPH-cytochrome P450 reductase and glyceryl trinitrate biotransformation by diphenyleneiodonium sulfate. Biochem. Pharmacol. 1998, 56, 881.
116. 2-formation. Biochem. J. 1993, 292, 545.
117. Kureishi, Y.; Lao, Z.; Shiojima, I.; et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt znd promotes angiogenesis in normocholesterolemic animals. Nat. Med. 2000, 6, 1004.
118. Feron, O.; Dessy, C.; Desager, J.P.; Balligand, J.L. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001, 103, 113.
119. Laufs, U.; Liao, J.K. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc. Med. 2000, 10, 143.
120. Vanhoutte, P.M. Endothelial dysfunction and inhibition of converting enzyme. Eur. Heart. J. 1998, 19 (suppl), J7.
121. Kogure, K.; Morita, M.; Hama, S.; Nakashima, S.; Tokumura, A.; Fukuzawa, K. Enhancement by alpha-tocopheryl hemisuccinate of nitric oxide production induced by lypopolysaccharide and interferon-gamma through the upregulation of protein kinase C in rat vascular smooth muscle cells. Eur. J. Biochem. 2002, 269, 2367.
122. Taddei, S.; Virdis, A.; Ghiadoni, L.; Salvetti, G.; Bernini, G.; Magagna, A.; Salvetti, A. Age-related reduction of NO availability and oxidative stress in humans. Hypertension. 2001, 38, 274.
123. Ignarro, L.J.; Buga, G.M.; Wei, L.H.; Bauer, P.M.; Wu, G.; del Soldato, P. Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc. Natl. Acad. Sci. USA 2001, 98, 4202.
124. Fiorucci, S.; Mencarelli, A,; Meneguzzi, A.; Lechi, A.; Morelli, A.; Del Soldato, P.; Minuz, P. NCX-4016 (NO-aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo. Circulation 2002, 106, 3120.
125. Wallace, J.L.; Mascara, M.N.; McKnight, W.; Dicay, M.; Del Soldato, P.; Cirino, G. In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX 4016. Thromb. Res. 1999 93, 43.
126. Momi, S.; Emerson, M.; Del Soldato, P.; Page, C.P.; Gresele, P. Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin. Eur. J. Pharmacol. 2000, 397, 177.
127. Momi, S.; Mezzasoma, A.M.; Leone, M.; Del Soldato, P.; Gresele, P. Nitroaspirin (NCX4016) plus clopidogrel versus aspirin plus clopidogrel in a model of thromboembolism in mice. Pathophys. Haemost. Thromb. 2002, 32 (Suppl. 2), 60.
128. Fredduzzi, S.; Mariucci, G.; Cantucci, M.; Del Soldato, P.; Ambrosiani, M.V. Nitro-aspirin (NCX4016) reduces brain damage induced by focal cerebral ischemia in the rat. Neurosci. Lett. 2001, 302, 121.
129. Rossoni, G.; Manfredi, B.; Colonna, V.D.; Bernareggi, M.; Berti, F. The nitroderivative of aspirin, NCX 4016, reduces infarct size caused by myocardial ischemia-reperfusion in the anesthetized rat. J. Pharmacol. Exp. Ther. 2001, 297, 380.
130. Wainwright, C.L.; Miller, A.M.; Work, L.M.; Del Soldato, P. NCX4016 (NO-aspirin) reduces infarct size and suppresses arrhythmias following myocardial ischaemia/reperfusion in pigs. Br. J. Pharmacol. 2002, 135, 1882.
131. Yu, J.; Rudic, R.D.; Sessa, W.C. Nitric oxide releasing aspirin decreases vascular injury by reducing inflammation and promoting apoptosis. Lab. Invest. 2002, 82, 825.
132. Momi, S.; Alberti, P.F.; Minuz, P.; Mezzasoma, A.M.; Leone, M.; Del Soldato, P.; Gresele, P. Effect of nitroaspirin (NCX 4016) plus clopidogrel versus aspirin plus clopidogrel on platelet pulmonary thromboembolism and on restenosis in mice. Thromb. Haemostas. 2004, Submitted for publication.
133. Takeuchi, K.; Yasuhiro, T.; Asada, Y.; Sugawa, Y. Role of nitric oxide in pathogenesis of aspirin-induced gastric mucosal damage in rats. Digestion 1998, 59, 298.
134. Fiorucci, S.; Santucci, l.; Gresle, P.; Faccino, R.M.; Del Soldato, P.; Morelli, A. Gastrointestinal safety of an NO-aspirin derivative (NCX 4016) in healthy humans in a randomized, double-blind, placebo controlled, endoscopic study. Gastroenterology 2003, 124, 842.
135. Gresle, P.; Momi, S.; Mezzasoma, A.M. NCX 4016: a novel antithrombotic agent. Dig. Dis. Liv. 2003, 35, 20.